Bringing the next generation of care closer to home

By Published On: November 4, 2026Last Updated: November 5, 2026
Bringing the next generation of care closer to home

How connected care can improve patient outcomes, strengthen NHS capacity and support access to advanced therapies

By Orlando Agrippa, founder and CEO, Sanius Health

Healthcare innovation is moving rapidly. Across rare diseases and blood cancers, new therapies and digital technologies are creating important opportunities for patients.

But the ability to improve outcomes also depends on what happens beyond the hospital: whether changing health is recognised, whether support is available, and whether clinical teams have the capacity to respond.

These questions have shaped Sanius Health’s approach to supporting patients beyond the hospital.

The company’s findings bring together reported improvements in quality of life, fewer patients recording acute events and the potential for substantial reductions in healthcare costs.

They also raise a wider question: how can healthcare systems turn better visibility of patients’ health into more effective care between appointments?

Connecting Technology with the Patient Experience

Wearable technology, patient-reported outcomes and longitudinal medical records each provide a valuable perspective on a person’s health.

Their combined value becomes clearer when the relationships between them are better understood.

A change in activity may mean something very different when accompanied by increasing pain, disrupted sleep or a recent change in treatment.

Equally, a patient’s account of feeling less well becomes more informative when it can be considered alongside their clinical history and patterns over the preceding days or weeks.

Bringing these sources together helps build a richer understanding of the individual and the factors shaping their health.

Sanius Health’s patient ecosystems connect these insights with education, engagement and support.

Patients can develop a better understanding of their own health patterns, while clinical colleagues gain access to information that can support more informed conversations and assessments.

Critically, the human element remains central. Technology needs to be accessible, patients need to understand its purpose, and there must be practical support around its use.

The company’s work with patients, clinicians and community partners continues to reinforce how important these relationships are in turning digital innovation into something useful in everyday life.

Findings from Sickle Cell Disease

Sickle cell disease has been a flagship area for Sanius and remains a powerful example of why this approach matters.

Vaso-occlusive crises can cause severe pain and substantial disruption to patients and families, with episodes frequently requiring emergency care or hospital admission.

An early analysis of Sanius Health’s sickle cell programme reported relative reductions of 52 per cent in the proportion of patients recording emergency attendances, 53 per cent for inpatient admissions and 64 per cent for vaso-occlusive crises following enrolment.

Alongside these findings, 53 per cent of patients assessed recorded an improvement in their EQ-5D-5L quality of life score between their first and most recent month.

These observational findings provide an encouraging foundation for the company’s work. They bring together two outcomes that should sit at the heart of healthcare innovation: how patients are feeling and the extent to which they require urgent hospital care.

Patient feedback has added an equally valuable perspective. Participants described gaining a clearer understanding of their health patterns, recognising their personal limits and making changes to daily routines, including sleep and activity.

This highlights the importance of giving people information they can understand and use, supported by an ecosystem that helps them remain engaged with their health.

Sanius Health’s ongoing research into predictive approaches builds on this foundation, exploring whether patterns in wearable and patient-reported data can help identify an approaching crisis.

The ambition is to create more opportunity for timely support, with patients and their clinical teams better informed about changes that may warrant attention.

The Wider Value for Healthcare Systems

The implications extend beyond individual programmes. For patients and families, fewer episodes of acute illness can mean less disruption to work, education and caring responsibilities.

For healthcare teams, reducing avoidable emergency use creates an opportunity to make better use of limited capacity.

Using the changes observed in Sanius Health’s early evaluation, an accompanying economic model applied reductions in the proportion of patients experiencing events and their annual frequency across a 500-patient population.

This estimated annual reductions in event-related costs of approximately £1.6 million for emergency attendances and £1.7 million for inpatient admissions.

These modelled estimates illustrate the potential scale of the opportunity, with the full economic benefit dependent on delivery costs and sustained outcomes.

They also reinforce why patient experience, clinical outcomes and resource use need to be considered together when evaluating new approaches to care.

Supporting Access to the Next Generation of Therapies

The question of capacity becomes particularly important as advanced therapies enter routine care.

In multiple myeloma, bispecific antibodies are creating new possibilities for patients, while bringing additional requirements for the clinical teams and services responsible for their care.

For an already stretched healthcare system, the ability to deliver these therapies depends on having the capacity, monitoring and patient support in place around them.

Indeed, treatment initiation and step-up dosing require careful management, including monitoring for complications such as cytokine release syndrome and neurological toxicity.

Developing ambulatory pathways for suitable patients therefore requires close coordination between specialist teams, nursing support and patients themselves, with clear arrangements for assessment and escalation.

Sanius Health’s bispecific patient support model is designed around these practical requirements.

Building on the company’s experience across rare blood conditions, the approach brings together a digital patient wallet, connected monitoring devices, non-clinical patient support and specialist nursing input, working alongside the patient’s existing treatment centre.

Practical support is built into the model, with onboarding, device provision and technical assistance intended to reduce additional demands on hospital teams and help patients use the service confidently.

Clinical monitoring and escalation follow agreed pathways, while treatment decisions remain with the responsible medical team.

Early NHS experience is beginning to demonstrate the potential resource benefit. In a single-centre evaluation presented at EHA 2026, Cambridge University Hospitals reported 50 inpatient bed-days avoided across 20 bispecific treatment-initiation episodes following the introduction of a virtual ward pathway.

This represented a 31 per cent reduction against expected inpatient use, with estimated direct savings of approximately £12,500 using local inpatient and virtual ward costs.

These findings provide an early example of how changing the support around treatment could help specialist services make better use of limited resources.

Building on the Opportunity

The next step is to make connected support a lasting part of how care is planned and funded.

Promising programmes need a clear route into routine services, with patients and clinical teams helping shape their development.

Investment in new treatments also needs to be matched by investment in the people and services that help patients benefit from them throughout their care.

Sanius Health’s ambition is to bring the next generation of care closer to home, building on its experience in sickle cell disease and extending that experience into support around advanced therapies.

Success will be measured in what patients experience: timely support, better access and more time spent well at home.

To discuss opportunities to develop this work with Sanius Health, contact [email protected].

Midstream Health secures US$20m Series A
NIPT: Wider screening does not always mean clearer answers